Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04893577 · ClinicalTrials.gov registry record · Phase 2
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04893577 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 10 participants.
The verdict
NCT04893577, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 20 subjects with documented herpes labialis. Patients will be treated with the study drug, EDTA Eye Drops or the active comparator of Abreva. Potential subjects will be assessed during a screening visit that must take place no greater than 2 weeks prior to the Day 1 (Baseline) visit. During the screening period, subjects that meet all other entry criteria will undergo UV susceptibility testing to determine their individual MED (minimal erythemal dose). UV susceptibility testing takes place over two days with exposure to UV light on specified regions on the subject's back followed by an assessment of the exposed areas 24 hours later to identify the MED. Subjects who have a measurable MED will be allowed to enroll in the study. Each subject will be randomly assigned in a 1:1 ratio to receive either EED or Comparator. Patients who express a cold sore will track the lesion with a diary card to rate their pain levels, and any unusual symptoms at Day 1, Day 3, Day 5, Day 7, and Day 10. Patients may also take photographs of the lesion throughout the study.
Interventions
- DRUG EDTA
- DRUG Abreva
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04893577
The ClinicalTrials.gov registry entry for NCT04893577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EDTA is the first listed.
NCT04893577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04893577 about?
NCT04893577 is a clinical study titled "EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions". This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 20 subjects with documented herpes labialis. Patients will be treated with the study drug, EDTA Eye Drops or the active comparator of Abreva. Potential subjects will be assessed during a screening visit that ...
What is the current status of trial NCT04893577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-01-20. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT04893577?
The interventions under investigation include: EDTA (DRUG), Abreva (DRUG).
Who is sponsoring clinical trial NCT04893577?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.